An Introduction to Leukaemia
Treating leukaemia holds numerous challenges, including the need for less toxic and more cost-effective treatments. Important additions to the landscape include targeted treatments such as FLT3 inhibitors, BCL-2 inhibitors and immune therapies such as monoclonal antibodies, antibody-drug conjugates and chimeric antigen receptor (CAR) T-cell therapies have been important additions to improve patient outcomes.
Expert video highlights, insights from the conference hub and comprehensive peer-reviewed articles from our journal portfolio provide updates on the changing treatment landscape. To learn more about how the latest developments impact on patient outcomes view our expert-led learning activities.
Treatment decisions in high-risk* acute myeloid leukaemia
Promotional content from Jazz Pharmaceuticals. Watch leading experts present and discuss the latest developments in the assessment and treatment of high-risk* acute myeloid leukaemia.
Advances and Future Goals in Acute Myeloid Leukaemia Therapy
touchREVIEWS in Oncology. 2022;18(2):130-8 DOI: https://doi.org/10.17925/OHR.2022.18.2.130
Acute myeloid leukaemia (AML) is a heterogeneous haematological malignancy characterized by the presence of ≥20% blasts in bone marrow or peripheral blood or the presence of defined genetic abnormalities.1 In 2020, there were an estimated 21,450 new patients with AML and 11,180 AML-related deaths in the USA.2 Most mutated myeloid stem cells proliferate due to genetic alterations, […]
PART ONE: Nicholas Short, EHA 2022: Ponatinib and blinatumomab in patients with PH+ALL: Results of a phase II study
In Part One of this video interview, Prof Nicholas Short (The University of Texas MD Anderson Cancer Center, Houston, TX, USA) discusses his phase II trial looking at ponatinib and blinatumomab for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia. A total of 55 patients were treated and the combination therapy showed complete molecular response. These […]
PART TWO: Nicholas Short, EHA 2022: Ponatinib and blinatumomab in patients with PH+ALL: Results of a phase II study
In Part Two of this video interview, Prof Nicholas Short (The University of Texas MD Anderson Cancer Center, Houston, TX, USA) summaries the rationale, design and eligibility criteria of his phase II trial looking at ponatinib and blinatumomab for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia, and summarizes the key take-home conclusions. A total of […]
Jorge Cortes, EHA 2022: Magrolimab plus azacitidine in the patients with AML and HR MDS
Professor Jorge Cortes (Georgia Cancer Center, Augusta, GA, USA) summarizes two more important abstracts from the 27th Congress of the European Hematology Association (EHA) looking at magrolimab, an antibody blocking CD47, “don’t eat me” signal on cancer cells. The first is a phase III trial (NCT05079230) assessing magrolimab in combination with venetoclax and azacitidine in […]
Jorge Cortes, EHA 2022: Updates from the QuANTUM-First trial of quizartinib versus placebo plus intensive chemotherapy in FLT3-ITD+ AML
Professor Jorge Cortes (Georgia Cancer Center, Augusta, GA, USA) summarizes one of his main highlights from the 27th Congress of the European Hematology Association (EHA). The phase III QuANTUM-First trial (NCT02668653) assessed quizartinib in relapsed/refractory FLT3–internal tandem duplication positive acute myeloid leukemia. The primary endpoint of the study was overall survival and this showed that […]
Jorge Cortes, ASCO 2022: Week 96 update of the ASCEMBL trial of asciminib versus bosutinib in patients with CML-CP
Professor Jorge Cortes (Georgia Cancer Center, Augusta, GA, USA) shares the long-term efficacy and safety data from the 96-week update of the ASCEMBL trial of asciminib with a novel mechanism of action in patients with Philadelphia chromosome-positive chronic myeloid leukaemia chronic phase. The abstract ‘Efficacy and safety results from ASCEMBL, a phase 3 study of […]
Barbara Eichhorst, EHA 2022: What did the GAIA/CLL13 study teach us about the impact of venetoclax and obinutuzumab in fit patients with CLL?
Prof Barbara Eichhorst (University Hospital Cologne, Cologne, Germany) discusses the impact of venetoclax plus obinutuzumab on the treatment of patients with chronic lymphocytic leukaemia (CLL) who are unfit for chemoimmunotherapy. The abstract ‘TIME-LIMITED VENETOCLAX-OBINUTUZUMAB +/- IBRUTINIB IS SUPERIOR TO CHEMOIMMUNOTHERAPY IN FRONTLINE CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): PFS CO-PRIMARY ENDPOINT OF THE RANDOMIZED PHASE 3 GAIA/CLL13 […]
Michael Mauro, ASH 2021: 48-Week Update of the Phase III ASCEMBL Trial
Professor Michael Mauro (Memorial Sloan Kettering Cancer Center, New York City, NY, USA) discusses the 48-week update from the ASCEMBL trial, a multicenter, open-label, phase III study of the efficacy and safety of asciminib, a first-in-class STAMP inhibitor, vs Bosutinib in patients with chronic myeloid leukemia in chronic phase after ≥2 prior tyrosine kinase inhibitors: […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!